Please login to the form below

Not currently logged in
Email:
Password:

ischaemic stroke

This page shows the latest ischaemic stroke news and features for those working in and with pharma, biotech and healthcare.

CETP inhibitor class finally dies as Merck abandons anacetrapib

CETP inhibitor class finally dies as Merck abandons anacetrapib

However, Merck's drug missed a key secondary objective, failing to reduce a composite outcome of major atherosclerotic events, which could have resulted from a lack of effect on ischaemic stroke,

Latest news

More from news
Approximately 1 fully matching, plus 34 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2016 Deal Watch January 2016

    245. Athersys/ Healios. Licence. Development and commercialisation of cell therapy treatments including MultiStem for the treatment of ischaemic stroke.

  • Medius Deal Watch table for March 2015 Medius Deal Watch table for March 2015

    225. Athersys / Chugai. Licence and collaboration Japan. Phase 2 stem cell therapy for treatment of ischaemic stroke.

  • The rise of chronic disease in BRIC markets The rise of chronic disease in BRIC markets

    Cardiovascular diseases – such as heart attack, stroke, DVT and atrial fibrillation – also present a major problem in Russia, with 46 per cent of self-reported sufferers (39 per cent being diagnosed). ... Analysts predict that ischaemic heart disease

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PharmiWeb Solutions

PharmiWeb Solutions creates, delivers and manages digital solutions for the pharmaceutical and healthcare segment. From digital marketing, to patient education...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics